keyword
MENU ▼
Read by QxMD icon Read
search

4CmenB

keyword
https://www.readbyqxmd.com/read/28637642/emergency-department-attendance-following-4-component-meningococcal-b-vaccination-in-infants
#1
Sarah Kapur, Thomas Bourke, Julie-Ann Maney, Paul Moriarty
INTRODUCTION: In September 2015, the UK became the first country in the world to introduce the 4-component meningococcal B vaccine(4CMenB) into the routine vaccine schedule for infants. 4CMenB is known to cause fever in infants. Infants presenting with fever, particularly those under 3 months, have a significant risk of serious bacterial infection(SBI). METHOD: Between September 2015 and January 2016, we performed a prospective audit of management of infants between 30 and 180 days attending the regional paediatric emergency department(ED) in Northern Ireland, within 4 days of receiving 4CMenB...
June 21, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28624305/durability-of-immunogenicity-and-strain-coverage-of-menbvac-a-meningococcal-vaccine-based-on-outer-membrane-vesicles-lessons-of-the-normandy-campaign
#2
Julien Sevestre, Eva Hong, Valérie Delbos, Aude Terrade, Eric Mallet, Ala-Eddine Deghmane, Ludovic Lemée, Muhamed-Kheir Taha, François Caron
OBJECTIVES: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine. METHODS: Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule...
July 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28533054/reduced-schedules-of-4cmenb-vaccine-in-infants-and-catch-up-series-in-children-immunogenicity-and-safety-results-from-a-randomised-open-label-phase-3b-trial
#3
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Lily Yin Weckx, Edson Duarte Moreira, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart...
June 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28524748/an-unwanted-guest-neisseria-meningitidis-carriage-risk-for-invasive-disease-and-the-impact-of-vaccination-with-insight-on-italy-incidence
#4
Elena Gianchecchi, Giulia Piccini, Alessandro Torelli, Rino Rappuoli, Emanuele Montomoli
Invasive Meningococcal Disease (IMD) represents a potentially life-threatening condition caused by Neisseria meningitidis. The disease is characterized by a case fatality rate of 5-10% whereas serious clinical sequelae can develop in survivors within 12-24 h from the first symptoms. However, IMD infection only occurs rarely, in fact, most of the interactions established between N. meningitidis and the host are harmless, and an estimated 10% of the population asymptomatically carries the bacterium in the nasopharynx...
May 29, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28483197/corrigendum-to-persistence-of-bactericidal-antibodies-following-booster-vaccination-with-4cmenb-at-12-18-or-24months-and-immunogenicity-of-a-fifth-dose-administered-at-4years-of-age-a-phase-3-extension-to-a-randomised-controlled-trial-vaccine-35-2017-395-402
#5
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Peter Dull, Andrew J Pollard
No abstract text is available yet for this article.
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28459837/predicted-strain-coverage-of-a-meningococcal-multicomponent-vaccine-4cmenb-in-portugal
#6
Maria João Simões, Célia Bettencourt, Rosita De Paola, Maria Giuliani, Mariagrazia Pizza, Monica Moschioni, Jorge Machado
OBJECTIVE: Although the incidence of meningococcal disease has been declining over the past decade in Portugal MenB meningococci is still an important cause of meningitis and sepsis. The aim of this study was to estimate the strain coverage of the 4CMenB vaccine in Portugal in order to support health policies for prevention and control of meningococcal disease. METHODS: Since 2002 the clinical and laboratory notification of meningococcal disease is mandatory in Portugal...
2017: PloS One
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#7
REVIEW
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28368526/discordant-effects-of-licensed-meningococcal-serogroup-b-vaccination-on-invasive-disease-and-nasal-colonization-in-a-humanized-mouse-model
#8
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background.: The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer membrane vesicle and recombinant protein-based vaccine licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods.: Using a "humanized" transgenic mouse model of nasal colonization, we took a systematic approach to estimate the potential for carriage prevention against antigenically diverse Neisseria meningitidis strains and to compare this protection to an invasive meningococcal disease challenge model...
May 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28366725/meningococcal-serogroup-b-strain-coverage-of-the-multicomponent-4cmenb-vaccine-with-corresponding-regional-distribution-and-clinical-characteristics-in-england-wales-and-northern-ireland-2007-08-and-2014-15-a-qualitative-and-quantitative-assessment
#9
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
July 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28366724/should-we-continue-to-monitor-4cmenb-coverage-with-mats
#10
Raquel Abad, Julio Vazquez
No abstract text is available yet for this article.
July 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28356256/recent-progress-in-the-prevention-of-serogroup-b-meningococcal-disease
#11
REVIEW
Ian M Feavers, Martin C J Maiden
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of 4 decades, vaccine development has focused on subcapsular protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies, and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations...
May 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28344804/multicomponent-meningococcal-b-vaccination-4cmenb-of-adolescents-and-college-students-in-the-united-states
#12
REVIEW
Angelika Banzhoff
Meningococcal disease is rare, easily misdiagnosed, and potentially deadly. Diagnosis in the early stages is difficult and the disease often progresses extremely rapidly. In North America, the incidence of invasive meningococcal disease (IMD) is highest in infants and young children, with a secondary peak in adolescents, a population predominantly responsible for the carriage of disease. Neisseria meningitidis serogroup B (MenB) accounts for a large proportion of meningococcal disease in North America, with documented outbreaks in three universities in the United States (US) during 2008-2013...
February 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28334397/does-post-implementation-vaccine-effectiveness-data-support-pre-implementation-predictions-of-4cmenb-utility
#13
REVIEW
Jamie Findlow, Ray Borrow
Meningococcal serogroup B vaccines have been licensed on the basis of safety and immunogenicity data without efficacy studies. Establishing the breadth of coverage of these new vaccines has proved difficult and relied on correlates of protection such as serum bactericidal antibody and a novel assays such as the meningococcal antigen typing system. The demonstration of the effectiveness of 4CMenB in a reduced infant dose schedule together with detailed phenotypic and genotypic information gained from isolates and sera from cases of invasive MenB disease in vaccine eligible infants will enable a re-evaluation of our knowledge of correlates of protection...
March 1, 2017: Pathogens and Disease
https://www.readbyqxmd.com/read/28318767/immunogenicity-and-safety-of-concomitant-administration-of-meningococcal-serogroup-b-4cmenb-and-serogroup-c-menc-crm-vaccines-in-infants-a-phase-3b-randomized-controlled-trial
#14
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). METHODS: Infants (N=251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5months (M3, M5) and a booster at 12months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12...
March 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28100432/effectiveness-and-impact-of-a-reduced-infant-schedule-of-4cmenb-vaccine-against-group-b-meningococcal-disease-in-england-a-national-observational-cohort-study
#15
Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun, Helen Campbell, Sonia Ribeiro, Charlotte Ward, Joanne M White, Ray Borrow, Mary E Ramsay, Shamez N Ladhani
BACKGROUND: In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England...
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/28100431/4cmenb-vaccine-effectiveness-reasons-for-optimism
#16
Nicole E Basta, Hannah Christensen
No abstract text is available yet for this article.
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/27914744/persistence-of-bactericidal-antibodies-following-booster-vaccination-with-4cmenb-at-12-18-or-24months-and-immunogenicity-of-a-fifth-dose-administered-at-4years-of-age-a-phase-3-extension-to-a-randomised-controlled-trial
#17
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Peter Dull, Andrew J Pollard
BACKGROUND: 4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24months and characterised the antibody response to a fifth dose administered at 4years of age. METHODS: A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four countries (number of centres): Czech Republic (nineteen), Italy (four), Spain (four) and the United Kingdom (four)...
January 5, 2017: Vaccine
https://www.readbyqxmd.com/read/27912986/a-phase-iii-observer-blind-randomized-controlled-study-to-evaluate-the-immune-response-and-the-correlation-with-nasopharyngeal-carriage-after-immunization-of-university-students-with-a-quadrivalent-meningococcal-acwy-glycoconjugate-or-serogroup-b-meningococcal
#18
Robert C Read, Peter Dull, Xilian Bai, Kate Nolan, Jamie Findlow, Rohit Bazaz, Annett Kleinschmidt, Maggie McCarthy, Huajun Wang, Daniela Toneatto, Ray Borrow
BACKGROUND: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningococcal carriage in vaccinated students. However, vaccine responses in university students and the impact of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined...
January 11, 2017: Vaccine
https://www.readbyqxmd.com/read/27468058/immunogenicity-of-a-meningococcal-b-vaccine-during-a-university-outbreak
#19
Nicole E Basta, Adel A F Mahmoud, Julian Wolfson, Alexander Ploss, Brigitte L Heller, Sarah Hanna, Peter Johnsen, Robin Izzo, Bryan T Grenfell, Jamie Findlow, Xilian Bai, Ray Borrow
BACKROUND: In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure on the basis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisseria meningitidis B at a U.S. university. Data suggested that vaccination would control the outbreak because isolates expressed antigens that were closely related to the vaccine antigens (factor H-binding protein [fHbp] and neisserial heparin-binding antigen). We quantified the immune responses induced by 4CMenB during the outbreak...
July 21, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27467048/characteristics-of-a-new-meningococcal-serogroup-b-vaccine-bivalent-rlp2086-menb-fhbp-trumenba%C3%A2
#20
REVIEW
Ashesh Gandhi, Paul Balmer, Laura J York
Neisseria meningitidis is a common cause of bacterial meningitis, often leading to permanent sequelae or death. N. meningitidis is classified into serogroups based on the composition of the bacterial capsular polysaccharide; the 6 major disease-causing serogroups are designated A, B, C, W, X, and Y. Four of the 6 disease-causing serogroups (A, C, Y, and W) can be effectively prevented with available quadrivalent capsular polysaccharide protein conjugate vaccines; however, capsular polysaccharide conjugate vaccines are not effective against meningococcal serogroup B (MnB)...
August 2016: Postgraduate Medicine
keyword
keyword
61758
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"